Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 12,508 matching trials from the live ClinicalTrials.gov search.
Filters: Miami, Florida Clear all
Recruiting Phase 2 Interventional

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

NCT05442216
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Tagraxofusp, Azacitidine, Venetoclax
Drug
Lead sponsor
Joshua Zeidner
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
7
States / cities
Miami, Florida • Orlando, Florida • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

NCT05259033
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
IcoSema, Semaglutide 1 mg
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
76
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Pregabalin In Adolescent Patients With Fibromyalgia

NCT01020526
View directory record Official record
Conditions
Fibromyalgia
Interventions
pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
21
States / cities
Los Angeles, California • Santa Ana, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 30, 2026, 10:42 AM EDT
Withdrawn Not applicable Interventional

Transoral Gastric Volume Reduction as an Intervention for Weight Management

NCT02578836
View directory record Official record
Conditions
Obesity, Overweight, Weight Loss
Interventions
Fogel Gastroplasty
Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 30, 2026, 10:42 AM EDT
Completed No phase listed Observational

Predicting the Safety and Effectiveness of Inferior Vena Cava Filters

NCT02381509
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
IVC Filter
Device
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older
Enrollment
1,428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
53
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 30, 2026, 10:42 AM EDT
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
View directory record Official record
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 30, 2026, 10:42 AM EDT
Not listed Phase 3 Interventional

ARISE - Aggressive Reduction of Inflammation Stops Events

NCT00066898
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease, Myocardial Infarction, Unstable Angina
Interventions
AGI-1067
Drug
Lead sponsor
AtheroGenics
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
128
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 108 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2006 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 3 Interventional

Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

NCT05439616
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Anaheim, California • Imperial, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CoolSculpting of the Distal Thigh Study

NCT02335749
View directory record Official record
Conditions
Body Fat Disorder
Interventions
The ZELTIQ System
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
22 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Miami, Florida • Chestnut Hill, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 3 Interventional

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

NCT06066528
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2
Interventions
Survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
34
States / cities
Anniston, Alabama • Phoenix, Arizona • Spring Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Not applicable Interventional

Online Exposure Therapy for Obsessive-Compulsive Disorder (OCD) Study

NCT06470893
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
OCD-NET
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 30, 2026, 10:42 AM EDT
Terminated Phase 3 Interventional Results available

Study of Tecovirimat for Human Mpox Virus

NCT05534984
View directory record Official record
Conditions
MPOX
Interventions
Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

Clinical Trial To Evaluate ANT-1207 In Subjects With Acne

NCT01293552
View directory record Official record
Conditions
Acne Vulgaris
Interventions
ANT-1207, Vehicle
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Miami, Florida • West Palm Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2013 · Synced Oct 30, 2026, 10:42 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

NCT05310071
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
130
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 30, 2026, 10:42 AM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Endocrine Therapy (ET)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
5,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
73
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

NCT01560793
View directory record Official record
Conditions
Influenza
Interventions
VAX161 [STF2.HA5 H5N1]
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 30, 2026, 10:42 AM EDT
Terminated Phase 1 Interventional Results available

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

NCT03582033
View directory record Official record
Conditions
Multiple Myeloma
Interventions
SEA-BCMA, dexamethasone, pomalidomide
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 30, 2026, 10:42 AM EDT
Recruiting Not applicable Interventional

Serious Gaming for Chemotherapy-induced Nausea and Vomiting

NCT05838638
View directory record Official record
Conditions
Neoplasms, Chemotherapy-induced Nausea and Vomiting
Interventions
eSSET-CINV
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
60 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 30, 2026, 10:42 AM EDT
Active, not recruiting Phase 2 Interventional

Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

NCT04690348
View directory record Official record
Conditions
Recurrent Brain Metastases
Interventions
Craniotomy, Cesium-131 brachytherapy
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

NCT03795428
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Pemziviptadil (PB1046) Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 3 Interventional

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

NCT05079919
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Chula Vista, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 10:42 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder

NCT01080807
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Matching Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Not applicable Interventional

The Development and Evaluation of a Single Session Intervention for Parent Distress Tolerance

NCT05955898
View directory record Official record
Conditions
Parents, Mental Health Issue, Distress, Emotional
Interventions
Parents THRIVE, Sharing Feelings Project
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 30, 2026, 10:42 AM EDT